Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 70518-3209

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 70518-3209). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rabeprazole Sodium 20mg 70518 3209 01

RABEprazole Sodium 20 mg delayed-release tablets label, quantity 30. The label includes the NDC number 70518-3209-01, manufacturer Advagen Pharma Limited, and repackager RemedyRepack Inc. Storage instructions and a QR code are also visible. The product is for oral use and prescription only.*

FDA Label Image

Remedy_label (Remedy Label)

Label for RABEprazole Sodium 20 mg delayed-release oral tablets, quantity 60, repackaged by RemedyRepack Inc. The label includes dosage form and strength, the NDC number 70518-3209-00, manufacturing information for Advagen Pharma Limited, and storage instructions. It also notes the product is prescription only (RX ONLY).*

FDA Label Image

Structural Image (Rabeprazole Dr Tablet 01)

Chemical structure of rabeprazole sodium, the active ingredient in rabeprazole sodium 20 mg delayed-release tablets by REMEDYREPACK INC. The structure shows the molecular layout including nitrogen, sulfur, oxygen, and sodium atoms as connected in the rabeprazole sodium compound.*

FDA Label Image

Figure 2: Mean Daytime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 02)

A line graph showing mean heartburn scores over a 28-day study period with baseline scores before day 0. The graph compares placebo and two doses of rabeprazole sodium (10 mg and 20 mg). Heartburn severity is rated from 0 (None) to 4 (Very Severe), with scores tracked daily.*

FDA Label Image

Figure 3: Mean Nighttime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 03)

A line graph depicting mean heartburn scores over a study period of 28 days, comparing placebo, rabeprazole sodium 10 mg, and rabeprazole sodium 20 mg groups. The x-axis represents study days, including a baseline period before day 0, and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe). Different line styles distinguish the three groups.*

FDA Label Image

Figure 4: Mean Daytime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 04)

A line graph comparing mean heartburn scores over time between a placebo group and a group taking 20 mg rabeprazole sodium tablets. The x-axis represents study days from -14 to 28, and the y-axis shows heartburn severity scores from 0 (none) to 4 (very severe). The graph shows a decline in heartburn scores for the rabeprazole group relative to placebo after study day 0.*

FDA Label Image

Figure 5: Mean Nighttime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 05)

A line graph comparing heartburn mean scores over a study period for two groups: placebo (n=58) and RAB 20 mg (n=59). The x-axis shows study days from -14 to 28, and the y-axis displays mean heartburn scores ranging from 0 (none) to 4 (very severe). The graph depicts a decrease in heartburn scores over time for the RAB 20 mg group compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.